Efficacy, public health impact and optimal use of the Takeda dengue vaccine
Cracknell Daniels, B.; Ferguson, N. M.; Dorigatti, I.
10.1101/2024.08.10.24311393 medRxivShow abstract
Dengue is the most common arboviral infection, causing substantial morbidity and mortality globally. The licensing of Qdenga, a second-generation vaccine developed by Takeda Pharmaceuticals, is therefore timely, but the potential public health impact of vaccination across transmission settings needs to be evaluated. To address this, we characterised Qdengas efficacy profile using mathematical models calibrated to published clinical trial data and estimated the public health impact of routine vaccine use. We find that efficacy depends on the infecting serotype, serological status, and age. We estimate that vaccination of children aged over six years in moderate to high dengue transmission settings (seroprevalence at 9 years of age > 60%) could reduce the burden of hospitalised dengue by 10-22% on average over ten years. We find some evidence of a risk of vaccine-induced disease enhancement in seronegative vaccine recipients for dengue serotypes 3 and 4, especially for children under six years of age. Because of this, the benefits of vaccination in lower transmission settings are more uncertain, and more data on the long-term efficacy of Qdenga against serotypes 3 and 4 are needed.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Estimating the optimal age for infant measles vaccination 96%
- Behaviour, booster vaccines and waning immunity: modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era 96%
- Maternal pertussis immunization and the blunting of routine vaccine effectiveness: A meta-analysis and modeling study 96%
Similar papers in this journal
- Identifying the role of household immunity in driving individual dengue virus infection risk 94%
- The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism 93%
- Effectiveness of mRNA and ChAdOx1 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario 92%
Similar papers in this journal
Similar papers in this journal
- Adherence and sustainability of interventions informing optimal control against COVID-19 pandemic 95%
- The potential impact of Omicron and future variants of concern on SARS-CoV-2 transmission dynamics and public health burden: a modelling study 94%
- Spatial analysis of COVID-19 booster vaccine uptake in Scotland, and projection of future distributions 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.